Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Blueprint Medicines Corp (BPMC)

Blueprint Medicines Corp (BPMC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,538,600
  • Shares Outstanding, K 61,200
  • Annual Sales, $ 249,380 K
  • Annual Income, $ -506,980 K
  • 60-Month Beta 0.63
  • Price/Sales 21.52
  • Price/Cash Flow N/A
  • Price/Book 40.82
Trade BPMC with:

Options Overview Details

View History
  • Implied Volatility 54.31% ( +8.39%)
  • Historical Volatility 63.41%
  • IV Percentile 64%
  • IV Rank 52.04%
  • IV High 74.91% on 01/05/24
  • IV Low 31.96% on 12/07/23
  • Put/Call Vol Ratio 1.99
  • Today's Volume 451
  • Volume Avg (30-Day) 409
  • Put/Call OI Ratio 0.76
  • Today's Open Interest 25,579
  • Open Int (30-Day) 26,318

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -1.65
  • Number of Estimates 10
  • High Estimate -1.45
  • Low Estimate -1.80
  • Prior Year -2.15
  • Growth Rate Est. (year over year) +23.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
80.42 +7.96%
on 02/22/24
101.00 -14.04%
on 02/28/24
-3.44 (-3.81%)
since 02/16/24
3-Month
72.24 +20.18%
on 02/14/24
101.00 -14.04%
on 02/28/24
-0.79 (-0.90%)
since 12/18/23
52-Week
41.54 +109.00%
on 04/05/23
101.00 -14.04%
on 02/28/24
+41.73 (+92.55%)
since 03/17/23

Most Recent Stories

More News
Blueprint Medicines: Q4 Earnings Snapshot

Blueprint Medicines: Q4 Earnings Snapshot

BPMC : 86.82 (-4.07%)
Chart of the Day: Does Blueprint Medicines Have a Blueprint for Success?

The Chart of the Day belongs to the cancer biomedical company Blueprint Medicines (BPMC) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical...

BPMC : 86.82 (-4.07%)
Why Blueprint Medicines Stock Soared Today

The precision-treatment company saw stronger-than-expected sales in its first full quarter following the launch of Ayvakit.

BPMC : 86.82 (-4.07%)
Blueprint Medicines: Q3 Earnings Snapshot

Blueprint Medicines: Q3 Earnings Snapshot

BPMC : 86.82 (-4.07%)
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective October 1, 2023, the Compensation Committee of Blueprint...

BPMC : 86.82 (-4.07%)
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective September 1, 2023, the Compensation Committee of Blueprint...

BPMC : 86.82 (-4.07%)
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective August 1, 2023, the Compensation Committee of Blueprint...

BPMC : 86.82 (-4.07%)
Why Shares of Blueprint Medicines Are Falling Wednesday

The company had generally improved earnings.

BPMC : 86.82 (-4.07%)
Blueprint Medicines: Q2 Earnings Snapshot

Blueprint Medicines: Q2 Earnings Snapshot

BPMC : 86.82 (-4.07%)
Blueprint Medicines Reports Second Quarter 2023 Results

/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the second quarter ended...

BPMC : 86.82 (-4.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Blueprint Medicines Corporation is a biopharmaceutical company focused on developing the potentially transformational precision medicines to address patients with genomically defined cancers and rare diseases.

See More

Key Turning Points

3rd Resistance Point 95.86
2nd Resistance Point 93.77
1st Resistance Point 90.29
Last Price 86.82
1st Support Level 84.72
2nd Support Level 82.63
3rd Support Level 79.15

See More

52-Week High 101.00
Last Price 86.82
Fibonacci 61.8% 78.29
Fibonacci 50% 71.27
Fibonacci 38.2% 64.25
52-Week Low 41.54

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar